137 related articles for article (PubMed ID: 38503521)
1. [Clinical characteristics and prognosis of newly diagnosed multiple myeloma patients with FGFR3 gene mutations].
Shen N; Zhang J; Xia Y; Shen XX; Wang J; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):989-994. PubMed ID: 38503521
[No Abstract] [Full Text] [Related]
2. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
Chen Z; Xia Y; Guo R; Zhang R; Qiu HR; Jin YY; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):408-413. PubMed ID: 35680599
[No Abstract] [Full Text] [Related]
3. [The impact of low T3 syndrome on the prognosis of patients with newly diagnosed multiple myeloma].
Zhang J; Zhang LN; Xia Y; Jin YY; Shen XX; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):216-221. PubMed ID: 37356983
[No Abstract] [Full Text] [Related]
4. Myc rearrangement redefines the stratification of high-risk multiple myeloma.
Jin X; Li H; Zhang D; Liu S; Song Y; Zhang F; Li Z; Zhuang J
Cancer Med; 2024 Jun; 13(11):e7194. PubMed ID: 38845529
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
Ho PJ; Brown RD; Spencer A; Jeffels M; Daniher D; Gibson J; Joshua DE
Leuk Lymphoma; 2012 Sep; 53(9):1728-34. PubMed ID: 22329352
[TBL] [Abstract][Full Text] [Related]
6. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.
Soverini S; Terragna C; Testoni N; Ruggeri D; Tosi P; Zamagni E; Cellini C; Cavo M; Baccarani M; Tura S; Martinelli G
Haematologica; 2002 Oct; 87(10):1036-40. PubMed ID: 12368157
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of the clinical effects and outcome of patients with double-hit high-risk multiple myeloma].
Liu S; Shang J; Lin Y; Wang ZH; Wei TN; Lin L; Yang T; Chen WM
Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1209-1214. PubMed ID: 34794226
[No Abstract] [Full Text] [Related]
8. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.
Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R
Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253
[TBL] [Abstract][Full Text] [Related]
9. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
Tao Y; Jin SW; Wang Y; Tang SJ; Liu YF; Xu J; Pan MM; Zhang WP; Mi JQ
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):48-54. PubMed ID: 36987723
[No Abstract] [Full Text] [Related]
10. [Analysis of clinical and prognostic characteristics of newly diagnosed multiple myeloma with myelofibrosis patients].
Zhang L; Li YL; Liu YM; Liu YB; Shang BJ; Cheng W; Dong XY; Zhu ZM
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(1):57-62. PubMed ID: 38178769
[No Abstract] [Full Text] [Related]
11. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
[No Abstract] [Full Text] [Related]
12. Prognostic value of semi-quantitative parameters of
Wan B; Zhang S; Wang P; Deng P; Dai W
Ann Nucl Med; 2023 Mar; 37(3):155-165. PubMed ID: 36528697
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma.
Chang H; Stewart AK; Qi XY; Li ZH; Yi QL; Trudel S
Blood; 2005 Jul; 106(1):353-5. PubMed ID: 15761022
[TBL] [Abstract][Full Text] [Related]
15. Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma.
Zhang L; Zhang R; Wang J; Chen Y; Qiao C; Shi Q; Jin Y; Shen X; Li J; Chen L
Clin Epigenetics; 2022 Jul; 14(1):93. PubMed ID: 35870987
[TBL] [Abstract][Full Text] [Related]
16. [Gene Mutation and Overexpression of Newly Diagnosed Multiple Myeloma Patients].
Fan Y; Wang SJ; Liu YF; Wang C; Li YF; Wang WQ; Hao QQ; Zhang DF; Li YM; Sun H; Guo R; Chen SQ; Xie XS; Li T; Wan DM; Jiang ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):166-169. PubMed ID: 35123621
[TBL] [Abstract][Full Text] [Related]
17. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
18. [Validation of the prognostic value of the Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma: A single-center study].
Xu Y; Shen XX; Jin YY; Li JY; Chen LJ; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):749-754. PubMed ID: 38049319
[No Abstract] [Full Text] [Related]
19. [Predictive Value of Pre-treatment Serum Uric Acid Level for Prognosis in Newly Diagnosed Patients with Multiple Myeloma].
Xu SQ; Zhao P; Wang ZH; Deng H; Zhang L; Wei J; Zou XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1216-1223. PubMed ID: 34362505
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
